Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13139937 | 0.89 | SMN1; SMN2 (0.59) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3072799 | 0.89 | SMN1; SMN2 (0.56) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL18172332 | 0.86 | SMN1; SMN2 (0.55) | HTTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL18496587 | 0.86 | HTT (0.55) | HTTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL29727685 | 0.86 | SMN1; SMN2 (0.55) | HTTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL18496608 | 0.85 | HTT (0.45) | HTTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL15874264 | 0.79 | SMN1; SMN2 (0.48) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL28009625 | 0.77 | SMN1; SMN2 (0.45) | HTTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL5505631 | 0.77 | KMT2A (0.63) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL310417 | 0.76 | HTT (0.53) | HTTSMN1; SMN2MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563049-B | Imidazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-109071451-B | Pyrazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-107531642-B | Imidazole derivatives | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-108137566-B | Triazole derivatives | 豪夫迈·罗氏有限公司 | 2021-05-25 | — | — | CN | disclosed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| CN-107922391-B | Pyridine and pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| EP-3359537-B1 | TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10005736-B1 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3334727-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-06-20 | — | — | EP | disclosed |
| US-20180162824-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| WO-2018069362-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-19 | — | — | WO | disclosed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017060202-A1 | TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017025523-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162824-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | MC3R, MC2R, NPY1R | HTT 1312/4885SMN1; SMN2 3356/4885MEN1 3098/4885 |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | HTT 1122/4885SMN1; SMN2 4697/4885MEN1 3613/4885 |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | DRD3, GABRR3, DRD4 | HTT 530/4885SMN1; SMN2 3964/4885MEN1 2608/4885 |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | HTT 678/4885SMN1; SMN2 4782/4885MEN1 2650/4885 |
| US-10005736-B1 | Pyridine and pyrimidine derivatives | MC3R, MC2R, NPY1R | HTT 1312/4885SMN1; SMN2 3356/4885MEN1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.